Distinguished in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Gulam A. Manji

Oncology | Hematology Oncology
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
Offers Telehealth
16 Years of Experience
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gulam Manji is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Manji has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Peripheral Nerve Sheath Tumor, and Familial Pancreatic Cancer.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Cholangiocarcinoma (Bile Duct Cancer).

Graduate Year
2009
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Group Health Cooperative
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
161 Fort Washington Ave, New York, NY 10032
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Nab-Paclitaxel, Gemcitabine, AB680 CD73 Inhibitor
Study Phase: Phase 1
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Azacitidine
Study Phase: Phase 2
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drugs: PLX3397, Sirolimus
Study Phase: Phase 1/Phase 2
Phase 1/2 Open-label Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Phase 1/2 Open-label Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drugs: Cobimetinib, Hydroxychloroquine, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Navitoclax, Sorafenib, Sorafenib Tosylate
Study Phase: Phase 1
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.
A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.
Enrollment Status: Completed
Publish Date: February 15, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Standard of care chemotherapy regimen
Study Phase: Phase 2
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug, Procedure
Study Drugs: Pegylated arginine deiminase, Gemcitabine, Docetaxel
Study Phase: Phase 2
A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
Enrollment Status: Suspended
Publish Date: April 20, 2023
Intervention Type: Drug, Biological
Study Drugs: BPX-601, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant Immunotherapy Based Combinations in Patients With Resectable PANCreatic Ductal Adenocarcinoma
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant Immunotherapy Based Combinations in Patients With Resectable PANCreatic Ductal Adenocarcinoma
Enrollment Status: Terminated
Publish Date: December 23, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

48 Total Publications

A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.
A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.
Journal: The oncologist
Published: March 17, 2025
Similar Doctors
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Ghassan K. Abou-Alfa
Oncology
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Ghassan K. Abou-Alfa
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (5.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ghassan Abou-Alfa is an Oncologist in New York, New York. Dr. Abou-Alfa is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Fibrolamellar Carcinoma, Liver Embolization, and Pancreaticoduodenectomy.

Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Aiwu R. He
Oncology | Hematology Oncology
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Aiwu R. He
Oncology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (0.1 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances

Aiwu He is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. He is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Fibrolamellar Carcinoma, Pancreatic Cancer, and Liver Embolization.

Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Andrea Cercek
Oncology | Hematology
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Andrea Cercek
Oncology | Hematology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (5.9 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrea Cercek is an Oncologist and a Hematologist in New York, New York. Dr. Cercek is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Lynch Syndrome, Hepatectomy, and Gallbladder Removal.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Manji's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile